USFDA approves use of Regeneron, Sanofi eczema drug Dupixent in adolescents

Dupixent was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.

U.S: The U.S. Food & Drug Administration on Monday approved the use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent for adolescents aged 12 and older, helping expand the use of an important revenue driver for both the companies in the world's largest market for drugs.

Read Also: Sanofi, Regeneron loses patent challenge to Amgen cholesterol drug Repatha

The drug was initially approved in 2017 and has since been launched in the United States as a treatment for adults with moderate-to-severe atopic dermatitis, as well as a drug for some asthma patients.

Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers seven major therapeutic areas namely cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines.

Whereas Regeneron is a biotechnology company founded in 1988, originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

Read Also: Sanofi, Regeneron slashes price of cholesterol drug by 60 percent